iBio, Inc.IBIONYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+26.1%
5Y CAGR+80.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+26.1%/yr
Quarterly compound
5Y CAGR
+80.3%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
19x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 106.52% |
| Q3 2025 | 15.04% |
| Q2 2025 | -26.88% |
| Q1 2025 | 8.42% |
| Q4 2024 | -2.11% |
| Q3 2024 | 29.50% |
| Q2 2024 | -20.54% |
| Q1 2024 | -8.07% |
| Q4 2023 | -10.19% |
| Q3 2023 | 27.89% |
| Q2 2023 | -20.51% |
| Q1 2023 | -58.39% |
| Q4 2022 | 53.18% |
| Q3 2022 | -52.03% |
| Q2 2022 | 99.51% |
| Q1 2022 | 22.52% |
| Q4 2021 | 28.95% |
| Q3 2021 | -49.37% |
| Q2 2021 | 25.09% |
| Q1 2021 | -6.21% |
| Q4 2020 | 5.59% |
| Q3 2020 | 106.03% |
| Q2 2020 | -12.59% |
| Q1 2020 | 15.42% |
| Q4 2019 | -13.56% |
| Q3 2019 | -7.38% |
| Q2 2019 | 13.36% |
| Q1 2019 | -16.18% |
| Q4 2018 | 18.18% |
| Q3 2018 | -4.14% |
| Q2 2018 | 14.97% |
| Q1 2018 | 0.70% |
| Q4 2017 | 3.56% |
| Q3 2017 | -13.68% |
| Q2 2017 | 2.01% |
| Q1 2017 | 20.67% |
| Q4 2016 | -4.78% |
| Q3 2016 | 13.47% |
| Q2 2016 | -9.45% |
| Q1 2016 | 42.70% |